microdosing a glp-1 of GLP-1's / Wellness Services / Services People Are Microdosing Weight-Loss Drugs
Description
JAMA 331 , 2041 (2024)
Those who meet these criteria may see significant health improvements and a reduction in the risks associated with obesity and related conditions
To our knowledge, there are limited published reports describing epiploic appendagitis occurring in the context of GLP-1/GIP receptor agonist-induced pharmacologic weight loss
For the body composition data that informed my tirzepatide choice, see tirzepatide vs semaglutide for athletes
New-found link between microbiota and obesity
